Neurocrine Biosciences (NBIX) News Today $102.88 -5.43 (-5.01%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$100.88 -2.00 (-1.94%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Neurocrine Biosciences Appoints Dr. Keswani as CMOApril 4 at 8:51 AM | tipranks.comNeurocrine Biosciences names Sanjay Keswani as chief medical officerApril 4 at 8:30 AM | seekingalpha.comNeurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical OfficerApril 4 at 8:00 AM | prnewswire.comHeadlands Technologies LLC Sells 13,566 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Headlands Technologies LLC lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 69.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,837 shares of the company's stock after selling 13,566 sharApril 4 at 5:20 AM | marketbeat.comWellington Management Group LLP Raises Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wellington Management Group LLP grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 102.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,457,425 shares of thApril 4 at 4:34 AM | marketbeat.comSchroder Investment Management Group Sells 84,539 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Schroder Investment Management Group decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 126,735 shares of the company's stockApril 4 at 4:14 AM | marketbeat.comAllstate Corp Purchases Shares of 2,909 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Allstate Corp acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,909 shares of the company's stock, valued at approximateApril 4 at 4:05 AM | marketbeat.comWells Fargo Sticks to Their Buy Rating for Neurocrine (NBIX)April 3 at 8:33 PM | markets.businessinsider.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by California Public Employees Retirement SystemCalifornia Public Employees Retirement System cut its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 453,091 shares of the company's stock after selling 9April 3 at 4:47 AM | marketbeat.comAmerican Century Companies Inc. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)American Century Companies Inc. lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 49.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 92,523 shares of the company's stock after selling 88,727 shApril 3 at 3:34 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $165.38 Average Price Target from BrokeragesApril 3 at 2:07 AM | americanbankingnews.comNomura Asset Management Co. Ltd. Sells 2,649 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Nomura Asset Management Co. Ltd. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,626 shares of the company's stoApril 2 at 4:24 AM | marketbeat.comUniSuper Management Pty Ltd Has $259,000 Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)UniSuper Management Pty Ltd lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 76.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,900 shares of the company's stock after sellinApril 2 at 4:15 AM | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Has $10.62 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 76,922 shares of the company's stock after buyingApril 2 at 4:07 AM | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Korea Investment CORPKorea Investment CORP lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,089 shares of the company's stock after sApril 2 at 4:06 AM | marketbeat.comPictet Asset Management Holding SA Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Pictet Asset Management Holding SA reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor ownMarch 31, 2025 | marketbeat.comNew Age Alpha Advisors LLC Acquires Shares of 22,363 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)New Age Alpha Advisors LLC bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 22,363 shares of the company's stock, valued at approximately $3,05March 31, 2025 | marketbeat.comElo Mutual Pension Insurance Co Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Elo Mutual Pension Insurance Co acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,0March 31, 2025 | marketbeat.com7,521 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by WINTON GROUP LtdWINTON GROUP Ltd acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,521 shares of the company's stock, valued at apprMarch 31, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twenty-three research firms that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendatiMarch 31, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by DnB Asset Management ASDnB Asset Management AS grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 118,227 sharesMarch 30, 2025 | marketbeat.comMitsubishi UFJ Trust & Banking Corp Cuts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mitsubishi UFJ Trust & Banking Corp trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,142 sharesMarch 30, 2025 | marketbeat.comVanguard Group Inc. Has $1.38 Billion Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Vanguard Group Inc. lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,119,641 shares of the company's stock after acqMarch 29, 2025 | marketbeat.comEagle Health Investments LP Purchases 26,400 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Eagle Health Investments LP grew its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 20.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 155,000 shares of the company's stock after buyinMarch 28, 2025 | marketbeat.comSegall Bryant & Hamill LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Segall Bryant & Hamill LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 28.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,870 shares of the company's stock after buyiMarch 28, 2025 | marketbeat.comNeurocrine price target raised to $184 from $183 at JPMorganMarch 27, 2025 | markets.businessinsider.comNeurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $184.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. raised their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a report on Wednesday.March 27, 2025 | marketbeat.comEFG Asset Management North America Corp. Sells 14,190 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)EFG Asset Management North America Corp. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 51.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 13,321 shares of the company's stock after selling 14,190 shares during the period.March 27, 2025 | marketbeat.comPrudential Financial Inc. Purchases 33,450 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Prudential Financial Inc. increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 18.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,175 sharesMarch 27, 2025 | marketbeat.comSei Investments Co. Reduces Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sei Investments Co. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 150,424 shares of the company's stoMarch 27, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Given New $184.00 Price Target at JPMorgan Chase & Co.March 27, 2025 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Corient Private Wealth LLCCorient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,927 shares of the company's stock after purchasing an adMarch 27, 2025 | marketbeat.comNeurocrine Biosciences: A Smart Biotech Bet With Blockbuster PotentialMarch 26, 2025 | fool.comDeep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)March 26, 2025 | benzinga.comCorebridge Financial Inc. Sells 4,872 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Corebridge Financial Inc. reduced its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 4.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 115,699 shares of the company's stock after selling 4,March 26, 2025 | marketbeat.comKLP Kapitalforvaltning AS Invests $4.75 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)KLP Kapitalforvaltning AS acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 34,800 shares of the company's stock, valued at approximMarch 26, 2025 | marketbeat.comTeacher Retirement System of Texas Purchases 3,974 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Teacher Retirement System of Texas lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 14.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,812 shares of the coMarch 25, 2025 | marketbeat.comSummit Global Investments Lowers Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Summit Global Investments lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,060 shares of the company's stockMarch 23, 2025 | marketbeat.comNatixis Advisors LLC Has $4.59 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Natixis Advisors LLC increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 14.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,604 shares of theMarch 23, 2025 | marketbeat.comVinva Investment Management Ltd Has $1.82 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Vinva Investment Management Ltd lowered its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 65.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,291 shares of the company's stock afteMarch 22, 2025 | marketbeat.comNeurocrine’s ingrezza shows efficacy in tardive dyskinesia studyMarch 21, 2025 | markets.businessinsider.comGenerali Asset Management SPA SGR Makes New $3.22 Million Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Generali Asset Management SPA SGR purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 23,605 shares of the company's stock, valuedMarch 21, 2025 | marketbeat.comNeurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) CapsulesMarch 20, 2025 | prnewswire.comFirst Financial Bankshares Inc Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)First Financial Bankshares Inc raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 26,942 shares of the company's stock after buying an additional 9March 20, 2025 | marketbeat.comThrivent Financial for Lutherans Purchases 711,970 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Thrivent Financial for Lutherans lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2,759.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 737,772 shares of the company'March 20, 2025 | marketbeat.comNeurocrine Biosciences (NASDAQ:NBIX) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Thursday.March 20, 2025 | marketbeat.comPrimecap Management Co. CA Sells 10,290 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Primecap Management Co. CA lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 393,710 shares of the company's stock after seMarch 19, 2025 | marketbeat.comNeurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comIs Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires?March 18, 2025 | msn.comProficio Capital Partners LLC Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Proficio Capital Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 34,535 shares of the company'March 18, 2025 | marketbeat.com Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.370.61▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼2014▲NBIX Articles Average Week Remove Ads Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today United Therapeutics News Today BioMarin Pharmaceutical News Today Incyte News Today Exelixis News Today Exact Sciences News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Repligen News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts